TD Cowen analyst Ritu Baral reiterated a Buy rating and $73.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "New FDA alignment on ~12mo eGFR to support full ataci' IgAN approval (from prior 24mo) strengthens ataci's early commercial launch positioning in IgAN. Key catalysts now include, beyond the July 7 PDUFA, ~12mo Ph3 eGFR data in 3Q26 (possibly @ ASN), sBLA submission in 4Q26 with full approval likely we think in mid/late 2027. Launch prep remains on track; we have confidence in a clean approval."

For an analyst ratings summary and ratings history on Vera Therapeutics click here. For more ratings news on Vera Therapeutics click here.

Shares of Vera Therapeutics closed at $33.94 yesterday.